The high cost of cancer drugs and what we can do about it
- PMID: 23036669
- PMCID: PMC3538397
- DOI: 10.1016/j.mayocp.2012.07.007
The high cost of cancer drugs and what we can do about it
Comment in
-
Integrating value assessment into discussions about the price of cancer drugs.Mayo Clin Proc. 2012 Oct;87(10):932-4. doi: 10.1016/j.mayocp.2012.08.009. Mayo Clin Proc. 2012. PMID: 23036668 Free PMC article. No abstract available.
-
The high cost of cancer drugs and what we can do about it.Mayo Clin Proc. 2013 Mar;88(3):306. doi: 10.1016/j.mayocp.2013.01.003. Epub 2013 Feb 27. Mayo Clin Proc. 2013. PMID: 23489458 No abstract available.
-
In reply.Mayo Clin Proc. 2013 Mar;88(3):306-7. doi: 10.1016/j.mayocp.2013.01.001. Epub 2013 Feb 27. Mayo Clin Proc. 2013. PMID: 23489459 No abstract available.
References
-
- Robert C., Thomas L., Bondarenko I. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526. - PubMed
-
- Meropol N.J., Schulman K.A. Cost of cancer care: issues and implications. J Clin Oncol. 2007;25(2):180–186. - PubMed
-
- Leveque D. Off-label use of anticancer drugs. Lancet Oncol. 2008;9(11):1102–1107. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
